Holen Sie sich die Stockscreener-App
16.24
4.10%
0.64
Vorhandelsmarkt:
16.05
-0.19
-1.17%
Schlusskurs vom Vortag:
$15.60
Offen:
$15.6
24-Stunden-Volumen:
1.19M
Relative Volume:
1.02
Marktkapitalisierung:
$1.68B
Einnahmen:
$71.78M
Nettoeinkommen (Verlust:
$-295.28M
KGV:
-5.1397
EPS:
-3.1597
Netto-Cashflow:
$-271.85M
1W Leistung:
+4.71%
1M Leistung:
+4.77%
6M Leistung:
+49.54%
1J Leistung:
+69.17%
1-Tages-Spanne:
$15.47
$16.50
1-Wochen-Bereich:
$15.42
$17.19
52-Wochen-Spanne:
$8.18
$22.50
Nurix Therapeutics Inc Stock (NRIX) Company Profile
Firmenname
Nurix Therapeutics Inc
Sektor
Branche
Telefon
(415) 660-5320
Adresse
1600 SIERRA POINT PKWY, BRISBANE
Compare NRIX vs VRTX, REGN, ARGX, ALNY, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
NRIX
Nurix Therapeutics Inc
|
16.24 | 1.61B | 71.78M | -295.28M | -271.85M | -3.1597 |
VRTX
Vertex Pharmaceuticals Inc
|
446.78 | 112.92B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
767.85 | 81.99B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
800.50 | 48.82B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
321.28 | 43.66B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
313.42 | 34.65B | 5.36B | 287.73M | 924.18M | 2.5229 |
Nurix Therapeutics Inc Stock (NRIX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-01-08 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2025-11-24 | Fortgesetzt | Truist | Buy |
| 2025-10-21 | Eingeleitet | Mizuho | Outperform |
| 2025-03-17 | Eingeleitet | Leerink Partners | Market Perform |
| 2024-12-10 | Eingeleitet | BTIG Research | Buy |
| 2024-12-06 | Eingeleitet | BMO Capital Markets | Outperform |
| 2024-10-24 | Eingeleitet | UBS | Buy |
| 2024-10-11 | Eingeleitet | Jefferies | Buy |
| 2024-09-06 | Fortgesetzt | Robert W. Baird | Outperform |
| 2024-07-31 | Eingeleitet | Truist | Buy |
| 2023-06-26 | Fortgesetzt | Oppenheimer | Outperform |
| 2023-03-09 | Eingeleitet | Barclays | Overweight |
| 2023-02-28 | Eingeleitet | Oppenheimer | Outperform |
| 2022-10-11 | Eingeleitet | Morgan Stanley | Equal-Weight |
| 2022-05-31 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2022-02-10 | Eingeleitet | Wells Fargo | Equal Weight |
| 2021-12-29 | Eingeleitet | H.C. Wainwright | Buy |
| 2021-10-14 | Eingeleitet | SVB Leerink | Outperform |
| 2021-06-04 | Fortgesetzt | Robert W. Baird | Outperform |
| 2021-04-30 | Fortgesetzt | Piper Sandler | Overweight |
| 2021-04-30 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2021-04-14 | Eingeleitet | Berenberg | Buy |
| 2020-11-19 | Eingeleitet | Robert W. Baird | Outperform |
| 2020-08-18 | Eingeleitet | JP Morgan | Overweight |
| 2020-08-18 | Eingeleitet | Needham | Buy |
| 2020-08-18 | Eingeleitet | Piper Sandler | Overweight |
| 2020-08-18 | Eingeleitet | Stifel | Buy |
Alle ansehen
Nurix Therapeutics Inc Aktie (NRIX) Neueste Nachrichten
How Weaker Q1 Results And Advancing Bexobrutideg Trials At Nurix Therapeutics (NRIX) Have Changed Its Investment Story - simplywall.st
Nurix: 'Strong Buy' Bexobruditeg Development And Dual Degrader Zelebrudomide (NASDAQ:NRIX) - Seeking Alpha
Nurix Therapeutics Inc reports results for the quarter ended February 28Earnings Summary - TradingView
Portfolio Recap: Is Nurix Therapeutics Inc undervalued by DCF analysis2026 Year in Review & Safe Capital Growth Plans - baoquankhu1.vn
NRIX: Wells Fargo Adjusts Price Target while Maintaining Overwei - GuruFocus
Nurix Therapeutics (NASDAQ:NRIX) Price Target Cut to $28.00 by Analysts at Wells Fargo & Company - MarketBeat
Inside Nurix Therapeutics Inc (NRIX): A Comprehensive SWOT Breakdown - GuruFocus
Nurix Therapeutics shares edge higher despite Q1 earnings miss - MSN
Nurix Therapeutics (NRIX) Stock Declines Amid Expanding Losses and R&D Investment - MEXC Exchange
Nurix Therapeutics (NRIX) Stock: Slides as Losses Widen Despite Pipeline Progress - CoinCentral
Needham & Company LLC Reaffirms "Buy" Rating for Nurix Therapeutics (NASDAQ:NRIX) - MarketBeat
NRIX: Needham Reiterates Buy Rating with Target Price of $26.00 | NRIX Stock News - GuruFocus
Nurix Advances NX-5948 Into Phase 3 Head-to-Head Battle in CLL/SLL - TipRanks
Nurix Therapeutics Reports First Quarter 2026 Financial Results and Provides a Corporate Update - Bitget
Nurix Therapeutics, Inc. (NRIX) Posts Q1 2026 Results - AlphaStreet
Nurix Therapeutics, Inc. (NRIX) reports Q1 loss, lags revenue estimates - MSN
Nurix Therapeutics, Inc. Q1 2026 Financial Results: Continued R&D Investment, Collaboration Revenue, and Key Risk Factors Highlighted in 10-Q Filing - Minichart
Nurix Therapeutics stocks rise 3% despite Q1 miss By Investing.com - Investing.com India
Nurix Therapeutics (NRIX) Q1 FY2026 Earnings: EPS -$0.79 (Miss v - GuruFocus
Nurix Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended February 28, 2026 - marketscreener.com
Nurix Therapeutics Reports Q1 2026 Financial Results and Corporate Update - Minichart
Nurix Therapeutics (NASDAQ:NRIX) Releases Quarterly Earnings Results, Misses Expectations By $0.03 EPS - MarketBeat
Nurix Therapeutics, Inc. (NRIX) Reports Q1 Loss, Lags Revenue Estimates - Yahoo Finance
NRIX Reports Lower Q1 Revenue; Focuses on Key Medical Developmen - GuruFocus
Nurix Therapeutics Fiscal Q1 Loss Widens, Revenue Falls - marketscreener.com
[10-Q] Nurix Therapeutics, Inc. Quarterly Earnings Report - Stock Titan
Earnings Flash (NRIX) Nurix Therapeutics, Inc. Reports Q1 Revenue $6.3M, vs. FactSet Est of $14.3M - marketscreener.com
Nurix Therapeutics 3Q 2026: Revenue $6.25M, EPS $(0.79) — 10-Q Summary - TradingView
Nurix Therapeutics Q1 loss widens on higher costs - TradingView
NRIX: Q1 2026 saw pipeline progress, higher R&D costs, and a strong cash position amid lower revenue - TradingView
Nurix Therapeutics (Nasdaq: NRIX) posts Q1 2026 revenue drop, wider loss - Stock Titan
Earnings Flash (NRIX) Nurix Therapeutics, Inc. Reports Q1 Revenue $6.3M, Vs. FactSet Est of $14.3M - Moomoo
Nurix pushes leukemia drug toward full approval with Phase 3 due mid-2026 - Stock Titan
Nurix Therapeutics to Participate in Upcoming Investor Conference - Bitget
Live April 13: Nurix CEO slated for Needham healthcare webcast - Stock Titan
Nurix Therapeutics (NRIX) Expected to Announce Quarterly Earnings on Tuesday - MarketBeat
U.S. Earnings Preview: After Market Close April 6 - Moomoo
Nurix Therapeutics (NASDAQ:NRIX) Trading 7.3% HigherStill a Buy? - MarketBeat
Dip Buying: Is Nurix Therapeutics Inc a stock for growth or value investorsTake Profit & Consistent Income Trade Ideas - baoquankhu1.vn
Nurix Therapeutics, Inc. (NASDAQ:NRIX) Receives Consensus Rating of "Moderate Buy" from Analysts - MarketBeat
Revenue Check: What is the next catalyst for Nurix Therapeutics Inc2026 Trading Volume Trends & Technical Entry and Exit Tips - baoquankhu1.vn
A Look At Nurix Therapeutics (NRIX) Valuation After Strong 1 Year Return And High Price To Sales Ratio - Yahoo Finance
NRIX Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
NRIX Technical Analysis & Stock Price Forecast - Intellectia AI
Analysts’ Top Healthcare Picks: Nurix Therapeutics (NRIX), Immunocore Holdings (IMCR) - The Globe and Mail
Nurix Therapeutics chief legal officer Ring sells $124k in stock - Investing.com Australia
Insider Sell: Christine Ring Sells Shares of Nurix Therapeutics Inc (NRIX) - GuruFocus
Nurix (NRIX) legal chief sells 8,148 shares under 10b5-1 plan - Stock Titan
8,148-Share Rule 144 Notice for NRIX (NASDAQ: NRIX) - Stock Titan
Institution Moves: What is the next catalyst for Nurix Therapeutics IncPortfolio Value Report & Real-Time Sentiment Analysis - baoquankhu1.vn
HC Wainwright & Co. Maintains Nurix Therapeutics (NRIX) Buy Recommendation - MSN
Finanzdaten der Nurix Therapeutics Inc-Aktie (NRIX)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.57%
1.10%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):